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Abstract 
Gastro retentive dosage forms have potential for use as controlled-
release drug delivery systems. Multiple unit systems avoid the “all-or-
none gastric” emptying nature of single-unit systems. A controlled 
release system designed to increase its residence time in the stomach 
with contact with the mucosa was achieved through the preparation of 
mucoadhesive microspheres by the emulsion solvent evaporation 
technique consisting of (I) chitosan mucoadhesive (ii) repaglinide, an 
oral hypoglycemic agent; and (iii) Eudragit RS-100 as polymer. The 
microspheres were evaluated for surface morphology and particle shape 
by scanning electron microscope.  The microspheres were also evaluated 
for their microencapsulation efficiency, in vitro wash-off mucoadhesion 
test, in vitro drug release and in vivo study. The microspheres were 
found to be spherical and free flowing. The microencapsulation 
efficiency was in the range of 61.44±1.16 to 79.90±1.17and 
microspheres exhibited good mucoadhesive property in the in vitro wash 
off test. The drug-polymer concentration of dispersed phase influences 
the particle size and drug release properties. All the formulations were 
followed by Matrix-Peppas model. The drug release was also found to 
be slow and extended for 24 h. In vivo testing of the mucoadhesive 
microspheres in diabetic albino rats demonstrated significant antidiabetic 
effect of repaglinide. The hypoglycemic effect obtained by 
mucoadhesive microspheres was for more than 16 whereas repaglinide 
produced an antidiabetic effect for only 10 h suggesting that 
mucoadhesive microspheres are a valuable system for the long term 
delivery of repaglinide. 
Keywords: Controlled Release, Repaglinide, Solvent Evaporation, 
Microspheres, Mucoadhesive. 
 
Introduction 
Microspheres are frequently used drug delivery 
system and may also possess mucoadhesive 
properties [1, 2]. Due to their micrometer size 
they may be applied to mucosa, where the other 
dosage forms, e.g. tablet, would represent a 
problem. Microencapsulation by various 
polymers and its applications are described in 
standard textbooks [3,4]. Microencapsulation has 
been accepted as a process to achieve controlled 
release and drug targeting. Microspheres are free 
flowing powder and having diameter of 1-
1000µm.Recently, dosage forms that can 
precisely control the release rates and targets 
drugs to a specific body site have made an 
enormous impact in the formulation and 
development of novel drug delivery system [2, 5]. 
Mucoadhesion has been a topic of interest in the 
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design of drug delivery systems to prolong the 
residence time of the dosage form at the site of 
application or absorption and to facilitate intimate 
contact of the dosage form with the underlying 
absorption surface to improve and enhance the 
bioavailability of drugs [6, 7]. Several studies 2 
reported mucoadhesive drug delivery systems in 
the form of tablets, films, patches, and gels for 
oral, buccal, nasal, ocular, and topical routes; 
however, very few reports on mucoadhesive 
microspheres are available [8,9].
 
The objective of 
this study is to develop, characterize, and 
evaluate mucoadhesive microspheres of 
repaglinide employing mucoadhesive polymers 
for prolonged gastrointestinal absorption. 
Repaglinide, an effective antidiabetic that 
requires controlled release owing to its short 
biological half-life [10]
 
of 1± 2 hours, was used 
as the core in microencapsulation. The 
mucoadhesive microspheres were evaluated by in 
vitro and in vivo methods for controlled release. 
Repaglinide, a fast and short-acting meglitinide 
analog was chosen as the drug candidate since it 
is indicated for the development of a dosage form 
with increased Gastric Residence Time. It has a 
very short half-life (1 h), low bioavailability 
(50%) and poor absorption in the upper intestinal 
tract [11, 12]. 
 
Material & Method 
Repaglinide was procured as a gift sample from 
Sun Pharma (Mumbai, India), Chitosan from 
CIFT (Cochin), Eudragit RS-100 from Evonik 
Degussa Pvt. Ltd. (Mumbai, India), Potassium 
dihydrogen phosphate (CDH, New Delhi), NaOH 
(Merck Ltd., Mumbai) HCl (Merck Ltd., 
Mumbai). All other reagents were of analytical 
grade obtained from standard companies. 
 
Method of Preparation of Formulation        
Microspheres were prepared by the solvent 
evaporation method using the solvents liquid 
paraffin/acetone. Different amounts of 
magnesium stearate were added to prevent 
agglomeration of microspheres. 
 
Eudragit RS-100 was first dissolved in acetone 
and adds chitosan hydrochloride powder. 
Repaglinide and different amounts of magnesium 
stearate were dispersed separately in acetone and 
added to the Eudragit RS-100 and chitosan 
hydrochloride dispersion. The mixture was 
emulsified in liquid paraffin. The emulsion was 
stirred at 1000 rpm, at 400 C for 40 min. The 
emulsion of microspheres was filtered, washed 
with n-hexane and dried in a vacuum at room 
temperature overnight. 
 
FTIR    
Spectrum of Repaglinide from 4000 cm -1 to 400 
cm -1 was obtained using FTIR 
spectrophotometer (Perkin Elmer BX) Using KBr 
pellet method. 
 
Formulation Development 
Various formulation were developed by changing 
the ratio of chitosan, Eudragit RS-100, solvent 
ratio, magnesium stearate and respective coded is 
given in the table1. 
 
Table 1. Formulation Design of Mucoadhesive Microspheres. 
Code Drug Chitosan Eudragit RS 100 Magnesium Stearate Methanol Acetone DCM 
RM-1 1 1 1 1 1 1 1 
RM-2 1 2 1 1 1 1 1 
RM-3 1 3 1 1 1 1 1 
RM-4 1 4 1 1 1 1 1 
RM-5 1 5 1 1 1 1 1 
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RM-6 1 1 2 1 1 1 1 
RM-7 1 1 3 1 1 1 1 
RM-8 1 1 4 1 1 1 1 
RM-9 1 1 5 1 1 1 1 
RM-10 1 1 1 1 2 1 1 
RM-11 1 1 1 1 1 2 1 
RM-12 1 1 1 1 1 1 2 
RM-13 1 1 1 2 1 1 1 
RM-14 1 1 1 3 1 1 1 
RM-15 1 1 1 4 1 1 1 
RM-16 1 1 1 5 1 1 1 
RM-17 1 1 1 6 1 1 1 
RM-18 1 1 1 1 2 2 1 
RM-19 1 1 1 1 1 2 2 
RM-20 1 1 1 1 2 1 2 
DCM- Dichloromethane, RM- Repaglinide Microspheres. 
 
Estimation of Repaglinide 
Repaglinide was estimated by ultraviolet visible 
(UV/Vis) spectrophotometeric method (Shimadzu 
UV-1700) based on the measurement of 
absorbance at 242.5 nm in 0.1N HCl pH 1.2. The 
method obeys Beer’s law in the concentration 
range of 1 to10 µg/ml. 
 
Determination of drug entrapment efficiency 
10mg of dried microspheres were weighted 
accurately and drug was extracted from 
microspheres by digesting for 24 hours in 10 ml 
of 6.8 pH phosphate buffer solution. During this 
period the suspension was agitated. After 24 hrs 
the suspension was centrifuged at 2000 rpm for 
about 3 minutes. The supernatant obtained was 
assayed spectrophotometrically for drug contents. 
The drug entrapment efficiency (DEE) was 
determined as: 
      
 
 
 
Particle size analysis 
The particle size of the microspheres was 
determined by using an Optical microscope 
(Magnus MLX-DX, Olympus). The 
mucoadhesive microspheres were examined by 
optical microscope. The freshly prepared 
microsphere was examined on an optical 
microscope and size of the microspheres was 
measured by using a pre-calibrated ocular 
micrometer and stage micrometer. About 200-
300 particles of each formulation were observed 
and counted 
 
Production Yield 
The percentage of production yield was 
calculated from the weight of dried Microspheres 
(W1) and the sum of initial dry weight of starting 
materials (W2) as the following formula: 
 
% Production Yield =W1/W2×100 
 
Drug entrapment efficiency, Particle size 
analysis, Production yield for formulation 1 to 20 
is respectively reported in Table 2. 
 
Table 2. Drug Entrapment Efficiency & Average Particle Size. 
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Formulation Code Drug Entrapment Efficiency Average Particle Size 
RM-1 62.82(±1.37) 64.0(±1.19) 
RM-2 67.59(±1.06) 69.1(±0.86) 
RM-3 71.69(±0.83) 73.0(±1.11) 
RM-4 74.26(±0.91) 75.0(±1.07) 
RM-5 79.90(±1.17) 78.3(±1.35) 
RM-6 65.76(±0.74) 65.1(±0.97) 
RM-7 68.34(±0.67) 67.2(±1.17) 
RM-8 72.34(±0.88) 71.3(±1.82) 
RM-9 77.94(±1.23) 74.1(±1.18) 
RM-10 63.80(±1.44) 63.6(±0.88) 
RM-11 61.53(±1.05) 62.0(±0.64) 
RM-12 62.61(±1.02) 64.2(±0.95) 
RM-13 64.94(±0.98) 66.1(±0.96) 
RM-14 63.42(±1.36) 61.4(±1.15) 
RM-15 61.44(±1.16) 57.2(±0.61) 
RM-16 65.18(±0.94) 52.1(±0.97) 
RM-17 60.73(±1.11) 48.7(±0.75) 
RM-18 64.05(±1.20) 61.2(±0.83) 
RM-19 66.12(±1.47) 63.3(±1.15) 
RM-20 69.69(±1.36) 67.4(±1.31) 
 
Scanning Electron Microscopy (SEM) 
SEM was performed for morphological 
characterization of microspheres using scanning 
electron microscope. They were mounted directly 
onto the SEM sample stub using double-sided 
sticking tape and coated with gold film 
(thickness,200nm)under reduced pressure 
(0.001mmHg), (Figure 1 and 2).  
 
        
Figure1. SEM of formulation RM-1.                                                   Figure 2. SEM of formulation RM- 10. 
In-vitro drug release 
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The release rate of Repaglinide from 
mucoadhesive microspheres was determined 
using dissolution testing apparatus 2 (paddle 
type). The dissolution test was performed using 
900 mL of 0.1N HCl, at 37± 0.50 C and 50 rpm. 
A sample (10 mL) of the solution was withdrawn 
from the dissolution apparatus hourly for 24 hrs, 
and the sample were replaced with fresh 
dissolution medium to maintain the sick 
condition. The samples were filtered through a 
membrane filter and diluted to a suitable 
concentration with 0.1N HCl. Absorbance of 
these solutions was measured at λmax 242 nm 
using a model 1700 Shimadzu, double-beam 
spectrophotometer. Cumulative percentage drug 
release was calculated using an equation obtained 
from a standard curve and same studies were 
performed in 6.8 pH phosphate buffer solutions. 
The drug release experiments were conducted in 
triplicate (n = 3). 
 
In-vitro Mucoadhesivity 
The mucoadhesive property of microspheres was 
evaluated by in-vitro wash off test for 
mucoadhesion. Pieces of intestinal mucosa 
(3cm×2cm) were mounted onto glass slides using 
cyanoacrylate glue. About 200 mg of 
microspheres were spread onto each wet rinsed 
tissue specimen and immediately thereafter the 
support was hung onto the arm of USP 
disintegration apparatus. By operating the 
disintegration test machine, the tissue specimen 
was given a regular up and down movement in 
0.1 N HCl/ PBS pH 6.8 at 37°C taken in a 1 liter 
vessel of the machine. At the end of 30 minutes, 
1 hour and then at hourly intervals, the machine 
was stopped and the microspheres adhering to the 
tissue, 0.1NHCl/PBS was centrifuged, dried and 
weight. The mucoadhesiveness of these 
microspheres was calculated. 
 
In-vivo Test 
The approval of the Institutional Animal Ethics 
Committee was obtained before starting the 
study. The approval number and date is 
716/02/a/CPCSEA and 25/10/2008 respectively. 
The study was conducted in accordance with 
standard institutional guidelines. In vivo 
evaluation studies for repaglinide mucoadhesive 
microspheres were performed in diabetics’ albino 
rats of either sex, weighing between 230-270g. 
After 16 h overnight fast, the experimental 
animals were made diabetic by single intravenous 
administration of cold, freshly prepared solution 
of alloxan (CDH New Delhi) at dose of 65-70 
mg/kg dissolved in normal saline solution. After 
1 week, animal with fasting blood glucose of 300 
mg/dl or more were considered diabetic and were 
used in the study. No food or liquid other than 
water was given during the experimental period. 
The product in the study was administered orally. 
After the confirmation of diabetes; the rats were 
divided randomly into three groups of four rats 
each and treated as follow: group1 was 
administered with 4 mg/kg body weight of 
repaglinide solution; group 2 was administered 
mucoadhesive microspheres and group 3 was 
administered marketed conventional repaglinide 
tablet. Blood samples were withdrawn by the 
retro orbital puncture at predetermined time at 1 
hour intervals up to 24 hours; Blood samples 
collected were allowed to clot without any 
anticoagulant and were centrifuged immediately 
at 5000 rpm for 20 minutes to separate the serum. 
The absorbance of the pink-colored solutions was 
measured in a spectrophotometer at 505 nm using 
a reagent blank. Serum glucose levels (mg/100 
mL) and percentage reduction in serum glucose 
levels were calculated.   
 
Results & Discussion  
Mucoadhesive Microspheres of Repaglinide 
consisting of chitosan hydrochloride powder in 
various combinations could be prepared by 
solvent evaporation of emulsification process. 
Microspheres with a coat of mucoadhesive 
polymer alone could not be prepared because of 
water insoluble nature of the polymers. 
 
The purity of drug sample was identified by 
scanning the drug sample on IR 
spectrophotometer. The peaks of the IR spectra of 
drug sample were found to be similar with the 
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standard IR spectra of pure repaglinide as 
reported. Figure 1 shows the I.R. spectra of 
Repaglinide. The I.R. spectra of mixture of drug 
and polymer indicated no incompatibility 
between drug and polymers, hence eudragit RS-
100, chitosan hydrochloride were chosen as 
polymers for further investigations. The spectrum 
of drug shows absorption bands at 3307.6 cm-1 N-
H stretching, 1635.99cm-1 N-H bending ,  2934.08 
cm-1 C-H2 Stretching  .The plain chitosan 
absorption peaks found at 3422.9 cm-1, 
2923.80cm-1, 1081.94 cm-1, 1640.31 cm-1.The 
plain eudragit RS-100 absorption peaks found at 
3448.52 cm-1, 2923.80 cm-1, 1081.94 cm-1, 
1640.31 cm-1. 
 
Surface morphology of the mucoadhesive 
microspheres was examined by scanning electron 
microscopy. The SEM showed that the 
microspheres were found roughly spherical and 
uniform in size. The size ranged from 48µm - 
78µm. 
 
The % age Production yield was increases with 
increase the concentration of the polymer. This 
was due to the fact that with increase in chitosan 
concentration, more amount of chitosan was 
added in the same volume of continuous phase.  
 
Particle size analysis of different formulations 
was done by optical microscopy. The average 
particle size was found to be in the range 
48.7±0.75 µm to 78.3±1.35 µm. Data for the 
particle sizes of microspheres of various 
formulations are shown in table No.2. For the 
purpose of accessing effect of polymer, 20 
formulations were prepared at different polymer 
concentrations. The mean particle size was 
significantly increases with increasing polymer 
concentration this may be due to high viscosity of 
polymer solution. High viscosity of polymer 
concentration requires high energy for breaking 
of droplets (table-2). We also observe that the 
mean particle size of microspheres was increased 
with increase in polymer concentration because 
higher viscosity of chitosan solution makes the 
microspheres more difficult to disperse; these 
results in larger size of microspheres are formed. 
 
 
 
Figure 3. FTIR spectrum of Repaglinide. 
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Table3. Bulk density and flow property. 
Formulation Code Bulk Density (g/ml) Tapped Density (g/ml) Carr’s Index Flow Property 
RM-1 0.4986 0.5814 14.24(±1.32) Excellent 
RM-2 0.5435 0.6236 12.84(±1.27) Excellent 
RM-3 0.6781 0.6493 10.96(±1.08) Excellent 
RM-4 0.5543 0.6237 11.12(±0.79) Excellent 
RM-5 0.4426 0.5126 13.65(±1.21) Excellent 
RM-6 0.6236 0.7136 14.43(±0.94) Excellent 
RM-7 0.5438 0.6432 15.45(±0.84) Good 
RM-8 0.4964 0.5836 14.95(±1.07) Good 
RM-9 0.4813 0.5446 11.94(±1.34) Excellent 
RM-10 0.6143 0.7234 15.08(±0.83) Excellent 
RM-11 0.6168 0.7136 13.56(±1.02) Good 
RM-12 0.5418 0.6183 12.36(±1.04) Excellent 
RM-13 0.5234 0.6243 16.16(±1.27) Good 
RM-14 0.4834 0.5434 11.04(±0.75) Excellent 
RM-15 0.4754 0.5845 15.24(±1.03) Good 
RM-16 0.6748 0.7113 13.56(±1.07) Excellent 
RM-17 0.6146 0.7233 15.02(±0.73) Good 
RM-18 0.6274 0.7154 12.30(±0.95) Excellent 
RM-19 0.4872 0.5698 14.49(±1.26) Excellent 
RM-20 0.6247 0.7234 14.70(±0.76) Excellent 
 
Percent drug entrapment efficiency of 
mucoadhesive microspheres was found in the 
range of 61.44±1.16 to 79.90±1.17 (table- 2). 
Formulation RM5 showed maximum % drug 
loading 79.90% whereas RM15 showed 
minimum % drug loading about 61.44% as 
compared to other formulations. The high 
entrapment efficiency of Repaglinide is believed 
to be due to its poor aqueous solubility in 
disperse phase. The percentage entrapment 
efficiency increased with increase in polymer 
concentration because higher viscosity of 
chitosan solution reduces the diffusion of the 
drug in the surroundings which does not allow 
entrapped particle to escape easily.  
Mucoadhesive microspheres of Repaglinide 
consisting of chitosan as a mucoadhesive 
polymers exhibited good mucoadhesive 
properties in the in-vitro wash off test for 
mucoadhesion. The wash off effect was slow in 
case of microspheres containing eudragit RS-100 
formulations containing chitosan showed better 
mucoadhesive properties. The wash off effect 
was faster at intestinal pH than at gastric pH. The 
rapid wash off effect observed at intestinal pH 
was due to ionization of carboxyl and other 
functional groups in the polymers at this pH 
which increases their solubility and also reduces 
adhesive strength. The strong interaction between 
chitosan microspheres and mucous glycoprotein 
and/or mucosal surfaces was found to be 
dependent upon the polymer concentration. As 
polymer concentration increases, the % 
mucoadhesion also increased as shown in table 4-
5.   
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Table 4. Percent of microspheres adhering to tissue at different times (h) in 0.1N HCl. 
Percent of microspheres adhering to tissue at different time Interval 
Formulation code 
1 2 4 6 8 
RM-1 78.3±1.6 70.2±0.9 57.6±0.9 34.8±1.2 20.4±2.0 
RM-2 80.7±0.9 71.4±1.6 58.6±1.6 36.4±0.9 21.8±0.9 
RM-3 81.6±2.0 73.5±2.0 59.7±2.3 37.1±1.9 23.7±1.6 
RM-4 82.8±2.5 74.6±2.0 62.3±0.9 39.6±2.0 25.6±0.9 
RM-5 84.1±3.4 75.2±3.4 64.1±1.2 40.8±2.5 27.1±1.6 
RM-6 77.9±1.2 69.6±0.9 56.8±1.9 33.4±2.6 19.6±0.9 
RM-7 79.6±1.6 71.8±1.4 57.9±2.5 34.6±1.9 20.2±1.9 
RM-8 80.1±2.0 72.9±1.6 59.7±3.4 36.1±1.6 21.3±2.0 
RM-9 82.6±0.9 74.9±2.0 62.8±0.9 37.2±0.9 23.8±2.5 
RM-10 76.6±0.6 75.8±0.4 63.1±1.9 39.9±2.5 24.1±3.4 
RM-11 78.2±1.4 68.5±1.2 56.1±2.0 33.4±2.0 19.6±1.2 
RM-12 77.9±0.9 69.7±2.5 57.9±1.6 32.1±0.9 18.7±0.9 
RM-13 79.4±2.0 70.1±1.8 58.4±1.9 34.5±1.2 20.4±1.9 
RM-14 76.2±2.5 68.4±1.9 60.7±2.5 35.1±2.0 21.9±0.9 
RM-15 80.6±3.4 71.5±0.9 59.4±2.0 32.7±2.5 22.7±2.0 
RM-16 78.5±1.2 72.7±0.6 56.2±0.9 33.4±2.6 19.5±2.5 
RM-17 77.5±1.9 69.6±3.4 57.3±1.6 36.1±1.9 21.2±2.4 
RM-18 79.1±0.9 68.4±1.2 59.3±1.8 35.8±0.9 20.1±2.0 
RM-19 77.6±0.6 67.1±2.4 61.2±2.0 34.4±1.6 18.6±1.9 
RM-20 78.4±1.2 70.1±0.9 56.1±0.9 37.8±0.9 17.9±1.6 
 
 
The more amounts of polymer results in higher 
amounts of free-NH2 -groups, which are 
responsible for binding with sialic acid groups in 
mucous membrane and this result in increase the 
mucoadhesive properties. In group RM5, % 
mucoadhesion was found to be 61.4% after 4 
hours, this formulation showing better 
mucoadhesive property, which was useful for 
drug release for longer period of time. 
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Table 5. Percent of microspheres adhering to tissue at different times (h) in PBS 6.8 pH. 
Percent of microspheres adhering to tissue at different times 
Interval Formulation 
code 
1 2 4 6 8 
RM-1 68.4±0.9 58.3±2.5 29.2±2.0 14.2±0.9 - 
RM-2 70.3±2.0 60.1±1.6 31.1±0.9 16.1±1.6 - 
RM-3 71.6±1.9 61.3±2.0 32.4±2.0 17.3±2.5 - 
RM-4 73.8±0.9 63.4±3.4 34.3±2.5 19.6±2.0 5.8±0.9 
RM-5 74.2±2.5 64.9±1.6 35.8±1.6 20.5±2.8 - 
RM-6 67.1±1.6 57.5±0.9 28.6±0.9 13.8±2.0 - 
RM-7 69.6±0.6 59.8±1.9 30.9±1.9 15.7±0.9 - 
RM-8 70.3±2.0 61.4±0.9 31.5±3.4 16.4±1.6 4.8±1.6 
RM-9 72.6±2.5 62.6±2.5 33.6±2.0 18.9±1.9 -- 
RM-10 72.8±0.9 56.8±2.0 27.1±1.6 14.1±3.4 -- 
RM-11 68.2±3.4 57.7±1.6 29.7±1.9 16.2±0.9 -- 
RM-12 69.1±1.6 58.8±0.9 28.1±2.0 17.9±1.6 -- 
RM-13 67.4±0.9 56.2±1.6 27.9±2.5 13.5±0.9 -- 
RM-14 66.5±2.0 58.9±0.9 28.6±0.9 14.6±1.9 -- 
RM-15 68.1±2.5 57.9±2.0 30.7±1.9 16.8±2.0 -- 
RM-16 67.8±0.9 55.4±3.4 31.4±2.0 15.9±2.5 -- 
RM-17 69.1±1.6 59.3±1.9 29.1±3.4 17.7±0.9 4.0±1.9 
RM-18 70.4±1.9 56.7±1.6 26.6±2.0 16.4±0.4 -- 
RM-19 66.7±2.0 57.1±2.0 27.8±0.9 18.8±1.2 -- 
RM-20 68.6±3.4 60.8±2.5 29.7±1.6 17.7±2.4 -- 
 
Drug release from the Microspheres was studied 
in phosphate buffer (pH6.8) and in 0.1 N HCl 
(pH 1.2). Drug release from the Microspheres 
was slow and dependent on the composition of 
the coat. It was also observed that the drug 
release was faster in 0.1 N HCl than in PBS 
which was perhaps due to the greater solubility of 
the drug in the former. It was found that the 
release profile of Repaglinide were different for 
the different formulations. Repaglinide release 
from these microspheres was slow, extended and 
dependent on the type of polymer used. Since the 
main aim of our study was to improve the 
bioadhesive strength of microspheres so these 
formulations were selected for the in-vitro release 
study.  Data for the release of the drug from 
microspheres of various formulations are shown 
in table No.4-8. 
 
In vivo studies in diabetic albino rats were 
performed with mucoadhesive microspheres of 
group RM5. From the in-vitro release study, 
formulation RM5 has shown good controlled 
release for more than 18 hours and thus it was 
selected for the in vivo study. The drug was 
administered at a dose equivalent to 4 mg/kg body 
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weight of repaglinide. Pure repaglinide and 
marketed conventional tablet were administered 
in a suspension form at the same dose. When pure 
repaglinide solution and tablet were administered, 
a rapid reduction in blood glucose levels were 
observed and maximum reduction of 47.71% and 
45.17% were observed respectively within 1h 
after oral administration. Blood glucose levels 
were recovered to the normal level in 14h (Fig.4). 
 
 
Table 6. Drug release profile of formulation RM1, RM2, RM3, and RM4 RM5& RM6 in 0.1 N HCl 
Time (h) RM1 RM2 RM3 RM4 RM5 RM6 
0 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
1 16.66±1.41 21.94±1.06 24.87±0.70 24.87±0.96 31.90±0.90 18.42±0.50
2 24.87±0.82 30.73±0.60 31.90±0.62 31.90±0.82 40.10±0.64 26.92±0.98
3 34.24±0.73 36.29±0.85 38.64±0.38 38.64±0.56 48.01±1.18 34.83±0.81
4 40.10±0.66 47.72±0.86 44.79±0.69 44.79±0.87 56.22±0.38 41.57±0.59
5 47.72±0.99 56.22±0.63 52.41±0.66 52.41±0.51 61.49±0.60 52.11±0.16
6 52.11±0.56 62.66±0.91 62.95±1.01 62.95±0.88 69.69±0.39 58.27±0.99
7 57.68±1.02 70.28±0.82 70.28±1.03 70.28±0.90 75.84±1.15 64.13±0.31
8 62.95±0.99 73.79±0.48 74.37±0.60 74.37±0.71 82.00±0.43 68.52±0.57
10 68.81±0.93 77.60±0.56 78.77±0.95 78.77±0.60 86.39±0.74 71.74±0.53
12 74.38±0.81 80.53±0.91 82.00±0.50 82.00±1.08 89.03±0.52 75.26±0.19
24 79.95±0.89 84.05±1.06 89.03±0.98 89.03±0.56 96.35±0.57 78.48±0.85
 
Table 7. Drug release profile of formulation RM6, RM7, RM8, RM9, RM10, RM11, & RM12 in 0.1 N HCl 
Time (h) RM7 RM8 RM9 
 
RM10 
 
 
RM11 
 
 
RM12 
 
0 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
1 16.08±0.15 19.59±0.97 21.94±1.35 13.74±0.48 11.68±1.18 8.17±0.32 
2 25.45±0.55 26.04±1.03 28.38±0.64 21.35±0.29 18.72±1.16 15.79±0.57
3 34.24±0.85 32.78±1.23 33.36±1.13 29.26±1.37 25.45±0.99 24.28±0.67
4 43.03±0.34 39.52±0.79 39.22±0.79 35.12±0.64 32.78±1.16 30.14±0.15
5 50.36±0.50 45.96±0.37 46.84±0.45 42.45±0.92 36.29±1.05 36.29±0.53
6 57.09±0.86 52.70±0.84 52.70±1.47 48.89±0.74 41.27±0.86 41.27±0.86
7 63.83±1.45 58.27±0.58 59.73±0.24 54.75±0.63 48.89±0.77 45.96±0.48
8 68.23±1.21 65.88±1.26 65.59±1.09 61.49±0.38 55.63±0.28 52.42±0.89
10 73.50±0.77 71.45±1.17 72.33±0.72 68.52±0.99 62.95±0.31 58.27±1.35
12 78.48±0.85 79.07±0.71 76.72±0.24 71.74±1.18 68.52±1.02 67.35±1.06
24 81.41±0.72 82.00±0.57 82.58±1.06 78.48±1.05 79.07±0.14 79.36±0.50
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A blood glucose level of 65-110 mg/dl is 
considered normal level. In the case of 
repaglinide mucoadhesive microspheres, the 
reduction in blood glucose levels was slow and 
reached maximum reduction within 3h after oral 
administration. This reduction in blood glucose 
level was sustained over longer periods of time. 
A 25% reduction in blood glucose level is 
considered a significant hypoglycemic effect. 
Significant hypoglycemic effect was maintained 
from 0.5 to 10 h after oral administration of 
repaglinide, whereas in case of mucoadhesive 
microspheres of repaglinide RM 5 significant 
hypoglycemic effect was maintained for a period 
of 2 to 16 h. The sustained hypoglycemic effect 
observed over a longer period of time in the case 
of mucoadhesive microspheres is due to the slow 
release and absorption of repaglinide over longer 
period of time. Repaglinide sustained release 
formulation is significantly more effective than 
the immediate release repaglinide formulation in 
reducing blood glucose levels and side effects. 
 
 
Table 9. Drug release profile of formulation RM13, RM14, RM15, RM 16,  RM 17& RM 18 in 0.1 N HCl. 
Time (h) RM13 RM14 RM15 RM16 RM17 RM18 
0 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
1 9.34±1.03 12.27±0.54 6.70±0.79 8.75±0.29 11.39±1.21 5.24±0.48 
2 16.08±1.15 21.94±0.58 12.56±0.71 16.66±0.92 19.59±1.26 12.86±0.64 
3 27.80±0.47 25.45±1.26 18.13±0.57 29.56±1.31 31.31±0.77 17.25±1.18 
4 36.29±0.53 30.43±1.13 27.50±0.64 37.17±1.18 39.52±0.85 23.99±0.99 
5 41.86±0.92 36.29±0.45 32.19±1.37 44.79±1.45 46.25±0.45 30.43±1.16 
6 50.94±0.38 41.57±0.72 42.45±1.06 57.87±0.37 53.58±1.47 36.29±0.31 
7 59.15±0.28 48.31±0.24 49.77±0.50 62.95±0.57 57.97±0.24 43.33±1.02 
8 68.52±0.69 53.58±0.34 55.92±0.32 67.93±0.24 59.36±0.72 49.48±0.63 
10 71.32±0.57 58.85±0.85 59.73±1.18 67.93±0.72 62.96±1.06 53.87±0.74 
12 74.63±1.16 65.30±0.72 63.54±0.99 70.12±0.55 68.81±1.17 66.32±0.48 
24 78.48±0.45 75.36±1.17 73.21±0.86 71.48±0.85 71.45±0.97 79.12±0.57 
 
Table 10. Drug release profile of formulation RM18, RM19, RM20, 0.1 N  HCl 
  Time (h) RM19 RM20 
0 0.00±0.00 0.00±0.00 
1 12.27±0.82 9.93±1.06 
2 18.42±0.51 13.74±0.82 
3 28.68±0.71 21.65±0.56 
4 36.29±1.08 27.50±0.62 
5 45.38±1.15 35.12±0.38 
6 56.80±0.57 43.91±1.01 
7 61.20±0.38 51.82±0.60 
8 66.76±0.64 58.56±0.95 
10 71.45±0.71 64.42±0.98 
12 77.02±0.19 70.57±0.80 
24 81.12±1.18 77.55±0.48 
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Figure 4. Showing the % reduction in blood glucose level 
 
Table 11. Percentage reduction in blood glucose level 
Percentage reduction in blood glucose level 
S.No. Time (h) 
Tablet Drug (control) Microspheres (RM5) 
1 0 0.00 0.00 0.00 
2 1 44.17 48.42 18.89 
3 2 35.20 37.20 31.20 
4 3 24.20 26.20 40.68 
5 4 23.12 22.20 36.66 
6 6 21.69 24.21 32.42 
7 8 19.12 20.20 30.26 
8 10 17.21 18.21 29.26 
9 12 9.68 11.50 26.97 
10 14 5.50 7.68 24.56 
11 16 2.52 4.25 15.25 
 
All release kinetic model were applied on 
RM2, RM5, RM9 and RM16 because of their 
good mucoadhesive property (table- 9&10). 
The best fit model was found to be matrix, 
some formulation showing Peppas also. The 
selection criterion for the best fit model was 
based on goodness of fit and residual sum of 
squares. The n value less than 0.5 indicating 
that transport follow Fickian trend. 
 
 
 
368
Yadav et al. International Journal of Drug Delivery 3 (2011) 357-370 
 
Conclusion   
The initial drug release significantly increased 
with an increase in the ratio of drug/polymer. An 
initial high release is observed due to the 
dissolution of surface adhered drug, where as the 
latter drug is due to the diffusion process, which 
is much slower when, compared to the initial 
release. Formulation RM5 was found to be the 
best among all the formulations since it showed 
good mucoadhesive properties, fair entrapment 
efficiency and could prolong the release for a 
longer duration of time.  Bulk density and flow 
property shows that most of the microspheres 
having good to excellent flow property. The ratio 
of drug/polymer also had effect on the release of 
the microspheres. The in-vivo study 
demonstrated significant blood glucose reducing 
activity of mucoadhesive microspheres of 
repaglinide. 
 
Microspheres of different size and drug content 
could be obtained by varying the formulation 
variables like polymer ratio, magnesium stearate 
ratio and solvent ratio. The multi-unit 
mucoadhesive repaglinide delivery system is 
accepted to provide clinician with a new choice 
of an economical, safe and more bio-available 
formulation in the management of moderate to 
severe diabetes mellitus. Therefore it may be 
concluded that drug loaded mucoadhesive 
microspheres are suitable delivery system for 
repaglinide.  
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